Elelyso® (taliglucerase alfa)

About Protalix BioTherapeutics

Protalix BioTherapeutics is a mission-driven company focused on transforming the treatment of rare diseases through its innovative plant cell-based protein expression platform, ProCellEx®. Its achievements include the successful FDA approval and commercialization of Elelyso® for Gaucher disease and a second approved product, establishing it as a leader in novel biologics manufacturing. The company's strategy centers on advancing its internal pipeline in lysosomal storage disorders while actively seeking strategic collaborations to expand the reach of its validated technology platform.

Therapeutic Areas